Board of Directors
Chairman, Board of Directors
Mr Lewin is Chair of the Board and Investment Committee for OneVentures Pty Ltd. He is a member of the Advisory Board of VGI Partners, a leading global investment firm based in Sydney and New York. Mr Lewin was a founding shareholding and Chair of the Advisory Board of OneVue (ASX: OVH) and was a founding shareholder and Executive Director of Reverse Corp (ASX: REF). Previously, he was a Managing Director of Ord Minnett and member of its Group Management Committee, a Principal of Elysium Capital Partners in London, a Managing Director (Equities) for Merrill Lynch in London after holding several positions in the Equities and Investment Banking divisions of SBC (now UBS) in London and SBC Dominguez Barry (now UBS) in Sydney.
Mr Lewin received a Bachelor of Commerce (First Class Honours) and a Bachelor of Laws (Honours) from University of Queensland. He was a visiting lecturer in business finance at the Queensland Institute of Technology. He received the Baillieu Research award in 1989.
Peter Gammell is currently the Executive Chairman of Invictus Advisory Pty Ltd and Non-Executive Chairman of Octet Finance Pty Ltd. Prior to this role he was Chief Executive Officer of Seven Group Holdings and Deputy Chairman of Australian Capital Equity Pty Ltd (ACE), the Western Australian based holding company associated with Mr. Kerry Stokes. He was the Managing Director of ACE for 21 years which is now one of Australia’s largest private companies.
He has served as a Director of Seven Network Ltd, RM Williams Ltd, National Hire Ltd, Consolidated Media Holdings Ltd and was the Chairman of Coates Hire. He led the creation of the Seven Media Group, a joint venture between Seven Network Limited and the private equity firm Kohlberg Kravis Roberts & Co. in 2006. In June 2010 Mr Gammell was appointed the Chief Executive Officer of Seven Group Holdings Limited, a public company listed on the Australian Stock Exchange which was formed as a result of the merger of Seven Network Limited and WesTrac Holdings Pty Ltd.
He currently serves as a Director of Seven West Media Limited (formed in 2011 by the merger of West Australian Newspapers Holdings with Seven Media Group), is a Director of Thinksmart Ltd, a UK based consumer finance company which is listed on AIM in London, and in January 2018, joined the Board of Directors of OneVentures Pty Ltd.
During Peter’s career he has been instrumental in acquiring and building multi-billion dollar enterprises with in excess of $10 billion of mergers and acquisitions.
Mr Gammell is a member of the Institute of Chartered Accountants of Scotland and holds a Bachelor of Science degree from the University of Edinburgh.
Roger is a director of OneVentures Pty Ltd, a technology venture capital firm, and is the principal shareholder and director of Eureka Capital Partners, a private investment concern. He is also a director of Illawarra Coke Company, an industrial land development concern.
Mr Massy-Greene previously served as the Chair of Ausgrid, Endeavour Energy and Essential Energy, having been appointed by the NSW government in 2012 to oversee reform of the NSW electricity distribution sector.
He previously co-founded the ASX 200 company Excel Coal Limited and its predecessor Resource Finance Corporation Ltd, and served as Chair of Excel Coal until its acquisition by Peabody Energy in 2006.
Mr Massy-Greene serves as Chair of Eureka Benevolent Foundation, a family foundation focused on overcoming socio-economic disadvantage. He is the President of Cranbrook School and a director of The Hunger Project in the USA and Australia.
Dr Michelle Deaker
Founding Partner & Managing Director
| BSc(Hons), MSc, PhD | Location: Sydney, AU
Dr Michelle Deaker is a Founding Partner & Managing Director of OneVentures and has been primarily responsible for the foundation of OneVentures firm and capital raisings of OneVentures Funds. The firm now has over $700M in funds under management. Michelle serves on the investment committee of OneVentures three main Funds, leads the technology practice within the firm and is responsible for investor relations managing the supervisory boards of OneVentures funds.
Michelle has over 20 years experience in the development of high growth technology companies in Australia and the US, has served on the boards of large and small listed and unlisted companies and has a strong background in Australian R&D and expertise in global business expansion. She has negotiated technology transfer contracts with research institutions; established financing syndicates with Australian, Asian and US investors; chaired the boards of several high growth companies; supported early breakthrough commercial contracts; leveraged her extensive networks for the benefit of OneVentures companies; and negotiated both financing and exit transactions.
Michelle established OneVentures in late 2006, coming into the venture capital industry as a successful IT industry business owner, entrepreneur and subsequently angel investor. The Company she founded in 1999, E Com Industries (www.giftvouchers.com), became the leading prepaid card and electronic voucher provider in Australia, servicing over 100 major retail brands including Coles Myer and Woolworths, managing $700M in Australian retail liability and eventually expanding operations into the United Kingdom, South Africa and New Zealand. E Com was acquired by UK publicly listed company, Retail Decisions, in 2005, in a transaction returning to investors 4.6x capital and an average IRR of 70%. Notably, E Com industries was one of only a handful of Australian companies that successfully migrated the dotcom boom and crash through to a successful outcome for investors. Prior to E Com Industries, Michelle established IT enterprise business, Networks Beyond 2000.
Michelle holds a Bachelor of Science (Honours 1st class), Master of Science and a PhD (Applied Science). She is a member of the Australian Institute of Company Directors and Chief Executive Women (CEW).
Portfolio Board Roles
In the news
Michelle’s previous board appointments include NICTA (now CSIRO’s Data61) and Seven West Media (ASX: SWM) along with OneVentures portfolio companies Smart Sparrow (Chair, acquired by Pearson), Hatchtech (Alt, Asset sale Dr Reddys (Nasdaq: DRL)), Vaxxas (Obs) and My Mobile Data / Sourse.AI.
Notable portfolio exits include part-sale of Employment Hero at 10x money. She has also served in advisory board roles with NSW Government’s Taskforce for the Digital Economy, Heads over Heels (supporting women entrepreneurs) and Australian Investment Council Venture Capital Working Group. She regularly provides lectures and working groups to finance and MBA students on venture capital including for the AIC, mentors new VC fund managers with a focus on female-led organisations and is a founding member of WinVC (Women-in-VC).
Dr Paul Kelly
Founding Partner & Director
| MBBS(Hons), MD, FRACP | Location: Sydney, AU
Dr Paul Kelly is Founding Partner & Director at OneVentures. Starting with his background as an Australian Physician, Paul has a long history of biotechnology entrepreneurship and healthcare investing, from developing innovation to commercialising at scale and realising substantial returns for investors.
Having returned to Australia in 2010 (after 15 years in the UK and US), he is dedicated to improving healthcare and treatment options for populations across the world. He lives and invests guided by his vision for a better future: through innovation, collaboration, and patient determination.
Paul is an avid reader and can regularly be found immersed in medical journals as well as fiction and non-fiction literature, which he believes “provides perspectives and insights that you would never get from management or business books”.
When he’s not mentoring and encouraging medical professionals to be entrepreneurial, he also looks after the health of our native environment: being highly active in bush regeneration and preservation.
Paul serves on the investment committees of OneVentures’ four main Funds, chairing the Fund III Investment Committee, and leading the healthcare and biotechnology practice across the firm.
Paul is a highly experienced executive and has multiple board responsibilities as either Chair or as a Non-Executive Director within numerous OneVentures portfolio companies. Independently of OneVentures, he is also a Non-Executive Director Garvan Institute of Medical Research
Paul has over 30 years’ experience in developing and commercialising biomedical innovations in the United States, Europe, United Kingdom and Australia. While in the UK and US he led early-stage and mid-stage companies, public and private, delivering strong returns for shareholders and investors as a founder and CEO.
Notably, Paul served as Co-Founder and CEO of Gemini Genomics (Nasdaq:GMNI), one of the world’s first clinical genomics companies, commercialising novel gene-based diagnostic and therapeutic targets. At Gemini, Paul led the company in one of the UK’s largest biotechnology IPOs of the time, completed strategic corporate acquisitions in Sweden and Canada, and negotiated collaborations with some of the world’s leading research institutions and biotechnology and pharmaceutical companies. In 2001, Paul led the company’s successful merger with Sequenom (Nasdaq:SQNM), valuing Gemini at over US$250M.
Paul’s other notable achievements include co-founding Agamatrix, now a leading bio-sensing medical device company with operations across the US and South East Asia, and Atomera (Nasdaq ATMR). He then served as President and CEO of Orchid Cellmark (Nasdaq:ORCH) – during his tenure revenues grew by over 50% in 2 years to $60M per annum, and increased the company valuation 10 fold.
While in the US Paul also served as President and CEO of Medcenter Solutions, a US based online medical education and pharmaceutical marketing company.
Before becoming a biotechnology executive, Paul had a distinguished career as a researcher and physician specialising in endocrinology at St Vincent’s Hospital, Sydney, Australia. While serving as a researcher at the Garvan Institute of Medical Research in Sydney, and in his postdoctoral work, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders, which have been published in leading journals such as Nature, New England Journal of Medicine, The Lancet, British Medical Journal and Proceedings of the National Academy of Science.
Paul has also served on a number of national governmental advisory bodies, as well as on the boards of public and private companies. He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008. He also serves on the UNSW Medicine Dean’s Advisory Group and serves on the Board of Directors of the Garvan Institute of Medical Research.
Portfolio Board Roles
In the news
07 October 2021
Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative Disease
02 June 2021
Preclinical studies from Vaxxas and Collaborators Reveal Potential of Vaxxas’ Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine
Co-Founder, Venture Partner & Director
| BSc(Hons), MBA, GAICD | Location: Brisbane, AU
Anne-Marie Birkill is a Co-Founder, Venture Partner, and Director of the Manager at OneVentures. She is well regarded for her passion for and experience of working with early-stage technology companies and entrepreneurs including as an expert advisor within the innovation community. She is based in Brisbane, a strong source of technology innovation opportunities.
Anne-Marie serves on the investment committees of OneVentures’ Funds I, II and III and the REM and Risk Management Committees. She is a director for OneVentures portfolio company Madorra and was Chair of the Board of Charm Health until 2017 when she lead the company to an acquisition by the Citadel Group (ASX:CGL). She originated Vaxxas in 2010 and was an observer to the Vaxxas Board until 2020.
Driven by a passion to grow Australia’s knowledge-based economy; Anne-Marie brings 35+ years’ experience in executive leadership, product development and commercialisation, advisory roles, mentorship, capital raising and exits to the team at OneVentures. Her interest in the innovation sector was forged during 15 years in leadership roles in agri-business companies developing and commercialising new cultivars of ornamental, aquatic, food, and forestry plants. Prior to co-founding OneVentures in 2010, she was CEO of i.lab Incubator, having previously spent five years in the senior management team at UniQuest. During this period Anne-Marie developed successful programs and networks to assist technology commercialisation, start-up formation and growth, capital raising and exit. She has experience of senior management and governance in listed and unlisted companies.
A committed advocate for diversity, equity and inclusion, Anne-Marie regularly contributes to thought leadership on this topic including via speaking engagements. For media and speaking enquiries, please contact us.
Her experience and reputation in the technology sector is demonstrated through her active participation in the innovation community. Her current external roles include appointment as an Industry Fellow with The University of Queensland (UQ) Business School, Chair of the Investment Committee for the UQ-lead “Trailblazer” Food and Beverage Accelerator, and director for InterFinancial Corporate Finance and the PPK Group (ASX:PPK).
Portfolio Board Roles
In the news
13 August 2018